期刊文献+

血清CA125异常患者疾病的统计分析 被引量:1

下载PDF
导出
摘要 目的通过统计分析评价患者血清CA125异常的临床意义。方法对Access全自动微粒子化学发光免疫分析系统测出的血清CA125异常的359例该院住院患者的确诊疾病进行分析。结果 CA125异常的359例患者中非肿瘤疾病发生率为71.87%;恶性肿瘤疾病发生率为22.84%;良性肿瘤疾病发生率为5.0%)。CA125异常非肿瘤疾病发生率较高的依次为,妇科疾病(16.99%)、消化道疾病(10.58%)、肝脏疾病(9.47%);CA125异常恶性肿瘤疾病发生率较高依次为肝癌(5.57%)、消化道恶性肿瘤(5.57%)、妇科恶性肿瘤(4.46%);良性肿瘤组CA125异常疾病发生率依次为卵巢良性肿瘤(2.79%)、子宫腺肌瘤(1.39%)、子宫平滑肌瘤(0.84%)。结论引起血清CA125异常的临床疾病种类繁多;CA125特异度不高,疾病的确诊需结合其他辅助检查。
出处 《国际检验医学杂志》 CAS 2014年第5期629-630,共2页 International Journal of Laboratory Medicine
  • 相关文献

参考文献11

  • 1易琳,刘兴明,林丁,黄学梅,刘预.血清CA153、CA125、CEA联合检测在乳腺癌诊断中的价值[J].重庆医科大学学报,2012,37(9):802-805. 被引量:87
  • 2Gubbels JA, Claussen N, Kapur AK, et al. The detection, treat ment and biology of epithelial ovarian caneer[J]. J Ovarian Res, 2010,3(1):8.
  • 3王艾丽,栾正云,李梅,罗冰,刘国瑞,黄梅.男性患者血清CA125水平增高的临床意义分析[J].临床检验杂志,2008,26(3):212-213. 被引量:6
  • 4Ueda Y,Enomoto T, Kimura T, ct al. Serum biomarkers for early detection of gynecologic cancers[J]. Cancers(Basel), 2010,2(2) : 1312-1327.
  • 5Donach M,Yu Y,Artioli G,et al. Combined use of biomarkers for detection of ovarian cancer in high-risk women [J]. Tumour Biol, 2010,31(3) :209 21,5.
  • 6Yurkovetsky Z, Skates S, I.omakin A, et al. Sevelopment of a mul- timarker assay for early detection of ovarian cancer[J]. J Clin On- col,2010,28(13):2159 2166.
  • 7王影,张晓霞,费军伟,刘艳丰,王毅.血清CA125在妇科疾病诊断中的临床意义[J].中国妇幼保健,2009,24(9):1188-1190. 被引量:15
  • 8仲召阳,王东,李增鹏,等.多肿瘤标志物蛋白质芯片榆测系统对结直肠癌诊断的临床意义[J].晕庆医学,2007,36(23):2406-2408.
  • 9Moore RG, MacLaughlan S,Bast RC Jr. Current state of biomark- er development for clinical application in epithelial ovarian cancer [J]. Gynecol Oncol,2010,116(2) :240-245.
  • 10Anand R,Markman M. Elevated Serum CA 125 in a Patient with Follicular Lymphorna and a History of Ovarian Cancer[J]. Case Rep Oncol,2011,4(1) :172 174.

二级参考文献28

  • 1姜建平,顾宇彤,李菁,杜宝君,徐胜荣.腺苷脱氨酶在胸腔积液鉴别诊断中的作用[J].临床肺科杂志,2006,11(1):14-15. 被引量:32
  • 2Tyronne I Goonewardene, Marcia R Hall. Management of asymptomatic patients on follow - up for ovarian cancer with rising CA - 125 concentrations [J].The Lancet Oncology, 2007, 8 (9): 813
  • 3Skates SJ , Xu FJ , Yu YH et al. Toward anoptimal algorilhmor ovarian cancer screening with longitudinal tumnr markers[J]. Cancer, 1999, 84 (2) : 454
  • 4Markmann S, Gerber B, Briese V. Prognostic value of CA125 levels During primary therapy [J]. Anticancer Res, 2007, 27 (4) : 1837
  • 5Moss EL, Hollingworth J, Reynolds TM. The role of CA125 in clinical practice [J]. Clin Pathol, 2005, 58:308
  • 6Cheng YM, Wang ST, Chou CY. Serum CA - 125 in preoperative patients at high risk for endometriosis[J]. Obstet Gynecol, 2002, 99 (5) : 375
  • 7Nikoli c B, Mitrovi? A, Lazi? J. Mean of CA 125 in making therapy decision in adnexal inflammalory tumors. Bosn [J]. Basic Med Sci, 2006, 6 (2): 3
  • 8Kabawat S E, Bast RC. Immunopathologic characterization of a monoclonal antibody that recognizes common surface antigens of human o- varian tumors of serous, endometrioid, and clear cell types[J]. Am J Clin Pathol,1983,79( 1 ) :98-104.
  • 9Moss E l,Hollingworth J. The role of CA125 in Clinical practice[J]. Clin Pathol,2005,58 ( 3 ) :308-312.
  • 10Elola M T, Chiesa M E, ALberti A F, et al. Galectin-1 receptors in different cell types [ J ]. J Biomed Sci,2005,12 ( 1 ) : 13-29.

共引文献126

同被引文献4

引证文献1

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部